CHMP Backs Baricitinib, Lifmior for Rheumatoid Arthritis CHMP Backs Baricitinib, Lifmior for Rheumatoid Arthritis

The EMA ' s CHMP recommended baricitinib for rheumatoid arthritis and Lifmior for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.International Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Alert Source Type: news